Intellectual Property partner Lisa Ferri (New York) and Litigation & Dispute Resolution partner Christopher Mikson (Washington DC) are quoted in this article discussing uncertainty surrounding Affordable Care Act provisions for licensing biosimilar products.

Downloads –